

# A mathematical model verifying potent oncolytic efficacy of M1 virus<sup>☆</sup>



Zizi Wang<sup>a,b</sup>, Zhiming Guo<sup>a,b,\*</sup>, Huaqin Peng<sup>a,b</sup>

<sup>a</sup> School of Mathematics and Information Science, Guangzhou University, Guangzhou 510006, PR China

<sup>b</sup> Key Laboratory of Mathematics and Interdisciplinary Science of Guangdong, Higher Education Institutes, Guangzhou University, Guangzhou 510006, PR China

## ARTICLE INFO

### Article history:

Received 16 September 2015

Revised 27 November 2015

Accepted 4 March 2016

Available online 11 March 2016

### MSC:

92C37

92C50

34D23

### Keywords:

Oncolytic virotherapy

M1 virus

Stability

Persistence

## ABSTRACT

Motivated by the latest findings in a recent medical experiment [19] which identify a naturally occurring alphavirus (M1) as a novel selective killer targeting zinc-finger antiviral protein (ZAP)-deficient cancer cells, we propose a mathematical model to illustrate the growth of normal cells, tumor cells and the M1 virus with limited nutrient. In order to better understand biological mechanisms, we discuss two cases of the model: without competition and with competition. In the first part, the explicit threshold conditions for the persistence of normal cells (or tumor cells) is obtained accompanying with the biological explanations. The second part indicates that when competing with tumor cells, the normal cells will extinct if M1 virus is ignored; Whereas, when M1 virus is considered, the growth trend of normal cells is similar to the one without competition. And by using uniformly strong repeller theorem, the minimum effective dosage of medication is explicitly found which is not reported in [19]. Furthermore, numerical simulations and corresponding biological interpretations are given to support our results.

© 2016 Elsevier Inc. All rights reserved.

## 1. Introduction

Despite of advances in cancer therapy over the past few decades, cancer is still a major health problem all over the world [13]. A useful treatment is anti-tumor immune response to tumors, which is usually cell-mediated with cytotoxic T lymphocytes (CTL) and natural killer (NK) cells playing a dominant role [16]. A number of mathematical models of the interactions between the immune system and a growing tumor have been developed [1,3–6,9,15–18,21–23,29,30]. The effector cells and tumor cells are concerned in these articles. With these models, numerical estimates of biologically significant parameters have been obtained, as well as some interpretations and predictions of a number of phenomena [16].

In recent years, oncolytic virotherapy has got an increasing attention since Martuza et al. [20] published an article in Science which claims that Transgene HSV has an influence on malignant glioma therapy. Oncolytic virotherapy is a growing treat-

ment modality that uses replicating viruses as selective antineoplastic agents. The tumor selectivity of oncolytic virus is primarily based on the genetic abnormalities of malignant cells, including innate immune defects, aberrant oncogenic signaling, and tumor-specific receptors [2,25,26]. Oncolytic Virotherapy also interests the mathematician. And mathematical modeling of oncolytic virus has provided useful insight into the understanding of underlying phenomena and offered helpful guidance to related public health decisions. For example, in 2005, Tao and Guo [27] formulated a PDE model to explore an explicit threshold of the intensity of the immune response for controlling the tumor and find a periodic solution; In 2010, Komarova and Wodarz [14] find two distinct types of dynamics depended on the virus spread; In 2011, a delayed oncolytic virus dynamics with continuous control, which points out that the Hopf bifurcation can occur as the delay crosses some critical values, is investigated by Wang et al. [31].

In 2014, Lin et al. [19] showed potent oncolytic efficacy and high tumor tropism of M1. The virus is engineered to selectively bind to receptors on the tumor cell surface (but not to the surface of normal healthy cells). The virus particles then gain entry by endocytosis and proceed to proliferate exponentially within the tumor cell, eventually causing death (lysis). Thus, they hypothesized that an apathogenic cancer cell-killing virus could be a candidate for systemic oncolytic therapy.

In order to better understand the role of the cell-killing virus of M1 discovered in Lin et al. [19], we formulate a mathematical

<sup>☆</sup> This work was partially supported by National Natural Science Foundation of China (No. 11371107), Program for Changjiang Scholars and Innovative Research Team in University (IRT1226) and Research Fund for the Doctoral Program of Higher Education of China (No. 20124410110001).

\* Corresponding author at: School of Mathematics and Information Science, Guangzhou University, Guangzhou 510006, PR China. Tel.: +86 13342886835.

E-mail address: [gzm100@21cn.com](mailto:gzm100@21cn.com), [guozm@gzhu.edu.cn](mailto:guozm@gzhu.edu.cn) (Z. Guo).

model to mimic the evolution of cell concentration described in the experimental study of Lin et al. [19]. The model is considered in the chemostat. Let  $S$  denote the concentration of nutrient,  $N$  the normal cell concentration,  $T$  the tumor cell concentration and  $M$  the M1 virus concentration. Our model is as follows.

$$\begin{cases} S'(t) = A - dS(t) - u_1S(t)N(t) - u_2S(t)T(t), \\ N'(t) = r_1u_1S(t)N(t) - (d + \varepsilon_1)N(t), \\ T'(t) = r_2u_2S(t)T(t) - (d + \varepsilon_2)T(t) - u_3T(t)M(t), \\ M'(t) = B + r_3u_3T(t)M(t) - (d + \varepsilon_3)M(t). \end{cases} \quad (1.1)$$

where  $A$  is the recruitment rate of nutrient,  $B$  is the recruitment of M1 virus which implies the minimum effective dosage of medication,  $d$  is the washout rate of nutrient and bacteria,  $u_i$  is the maximal growth rate,  $r_i$  is the yield constant of nutrient to biomass of the organism,  $\varepsilon_i$  is the natural death rate of biomass. It is easy to see that the relationship between nutrient and normal cells or tumors is prey and predator, and the relationship between normal cells and tumors is competitive. This type of model had been researched deeply, such as Hsu et al. [11,12], Wang and Zou [32].

But our research perspective is different from previous researches. In order to express the potent oncolytic efficacy and high tumor tropism of M1, we divide the model into three part:  $S-N$  model,  $S-N-T$  model, and  $S-N-T-M$  model. The  $S-N$  model reflects the growth trend of normal cells of healthy individuals, while the  $S-N-T$  model reflects the growth trend of cells of people with cancer, and the  $S-N-T-M$  model will explain the experimental findings [19] on potent oncolytic efficacy and high tumor tropism of M1.

Now, we prove that solutions to the model (1.1) possess long-time behavior.

By the form of (1.1), it is easy to see that solutions to (1.1) with nonnegative initial values are nonnegative, and the solutions with positive initial values are positive. Set

$$W(t) = S(t) + \frac{1}{r_1}N(t) + \frac{1}{r_2}T(t) + \frac{1}{r_2r_3}M(t). \quad (1.2)$$

Differentiating (1.2) with respect to  $t$ , we find

$$\begin{aligned} \frac{dW(t)}{dt} &= A + \frac{B}{r_2r_3} - dS(t) - \frac{d + \varepsilon_1}{r_1}N(t) \\ &\quad - \frac{d + \varepsilon_2}{r_2}T(t) - \frac{d + \varepsilon_3}{r_2r_3}M(t), \\ &\leq A_1 - dW(t). \end{aligned} \quad (1.3)$$

where  $A_1 = A + \frac{B}{r_2r_3}$ . By differentiating inequality above, it is easy to see that

$$W(t) \leq \frac{A_1}{d} + 1, \text{ for all large } t.$$

It is showed that model (1.1) is as well behaved as one intuitus from biology. In the sequel, we consider the model in the first quadrant.

The rest of this paper is organized as follows. In Section 2, the  $S-N$  model is considered, in which the evolution of normal cells without tumor cells is discussed. Similarly,  $S-T$  model is studied. In Section 3, it is proved that the existence of tumor cells may interrupts the growth of normal cells; on the other hand, from the  $S-N-T-M$  model, we can see that the growth trend of normal cells is similar to the  $S-N$  model which explain the experimental findings [19] that M1 virus is of potent oncolytic efficacy and high tumor tropism; Section 4 is devoted to numerical simulations. Finally, short conclusion is given in Section 5.

## 2. The model without competition

### 2.1. The $S-N$ model

From the system (1.1), the  $S-N$  model is given by the following form.

$$\begin{cases} S'(t) = A - dS(t) - u_1S(t)N(t), \\ N'(t) = r_1u_1S(t)N(t) - (d + \varepsilon_1)N(t). \end{cases} \quad (2.1)$$

It is easy to see that system (2.1) always has an equilibrium  $E_{01} = (\frac{A}{d}, 0)$ . Similar to the definition of basic reproduction number [8,24], we define a threshold value

$$Q_1 = \frac{Ar_1u_1}{d(d + \varepsilon_1)}, \quad (2.2)$$

where  $\frac{1}{d}$  is the average lifetime in compartment  $S$ , then every individual in compartment  $S$  product  $A/d$  individuals. Similarly,  $1/(d + \varepsilon_1)$  is the average lifetime in compartment  $N$ , and the product rate of every individual in compartment  $N$  is  $(r_1u_1S)/(d + \varepsilon_1)$ . Thus, the number  $Q_1 = (Ar_1u_1)/d(d + \varepsilon_1)$  reflects the ability of absorbing nutrients, we call it absorbing number.

If absorbing number  $Q_1 > 1$ , then there is a positive equilibrium

$$E_{02} = \left( \frac{d + \varepsilon_1}{r_1u_1}, \frac{Ar_1u_1 - d(d + \varepsilon_1)}{u_1(d + \varepsilon_1)} \right).$$

Next, we show that the stability of equilibrium depends on the absorbing number  $Q_1$ .

**Theorem 2.1.** *The local stability of equilibrium  $E_{01}$  and  $E_{02}$  have following conclusions.*

- (i) If  $Q_1 < 1$ , then the equilibrium  $E_{01}$  is locally asymptotically stable;
- (ii) If  $Q_1 > 1$ , then the equilibrium  $E_{01}$  is unstable, and the positive equilibrium  $E_{02}$  is locally asymptotically stable.

**Proof.** We linearize the system (2.1) at the equilibrium  $E_{01}$ , and obtain the following characteristic equation.

$$(\lambda + d) \left( \lambda - \frac{Ar_1u_1 - d(d + \varepsilon_1)}{d} \right) = 0.$$

It is obvious that  $\lambda_1 = -d$  and  $\lambda_2 = \frac{Ar_1u_1 - d(d + \varepsilon_1)}{d} = (d + \varepsilon_1)(Q_1 - 1)$ . Thus when  $Q_1 < 1$ ,  $\lambda_2 < 0$ , and the equilibrium  $E_{01}$  is locally asymptotically stable, while it is unstable when absorbing number  $Q_1 > 1$ .

As we know, the positive equilibrium  $E_{02}$  exists if and only if  $Q_1 > 1$ . By direct computation, the characteristic equation of (2.1) at  $E_{02}$  becomes

$$\lambda^2 + dQ_1\lambda + d(d + \varepsilon)(Q_1 - 1) = 0. \quad (2.3)$$

Clearly, if  $Q_1 > 1$ , then the positive equilibrium  $E_{02}$  is locally asymptotically stable.  $\square$

**Theorem 2.2.** *System (2.1) does not have nontrivial periodic orbits in the set  $\Gamma = \{(S, N) | S > 0, N > 0\}$ .*

**Proof.** Consider system (2.1) for  $S \geq 0$  and  $N \geq 0$ , and we define  $P(S, N) = A - dS - u_1SN$ ,  $Q(S, N) = r_1u_1SN - (d + \varepsilon_1)N$ . Take a Dulac function

$$D(S, N) = \frac{1}{SN}.$$

We have

$$\frac{\partial(DP)}{\partial S} + \frac{\partial(DQ)}{\partial N} = -\frac{A}{NS^2} < 0, \forall S > 0, N > 0.$$

The conclusion follows.  $\square$

By Theorems 2.1 and 2.2, the following result is obvious.

**Theorem 2.3.** System (2.1) has the following global dynamics.

- (i) If  $Q_1 \leq 1$ , then system (2.1) has a unique equilibrium. The equilibrium  $E_{01}$  of system (2.1) is globally asymptotically stable in the set  $\Omega = \{(S, N) | S \geq 0, N \geq 0\}$ ;
- (ii) If  $Q_1 > 1$ , then the system (2.1) has two equilibria,  $E_{01}$  and  $E_{02}$ . Moreover, the positive equilibrium  $E_{02}$  is globally asymptotically stable in the set  $\Omega' = \{(S, N) | S \geq 0, N > 0\}$ .

**Proof.** By Theorem 2.1, we know that equilibrium  $E_{01}$  (or  $E_{02}$ ) is locally asymptotically stable when  $Q_1 < 1$  (or  $Q_1 > 1$ ). Then by Theorem 2.2, we can see that the result is obvious when  $Q_1 < 1$  or  $Q_1 > 1$ . So we consider  $Q_1 = 1$ , set

$$V_0(S, N) = S - \frac{A}{d} - \frac{A}{d} \ln \frac{dS}{A} + \frac{N}{r_1}.$$

Differentiating  $V_0$  with respect  $t$  along solutions of (2.1) in  $\Omega$ ,

$$\frac{dV_0}{dt} = -\frac{(A-dS)^2}{dS} + \left( \frac{u_1 A}{d} - \frac{d+\varepsilon_1}{r_1} \right) N.$$

As  $Q_1 = 1$ , then  $\frac{u_1 A}{d} - \frac{d+\varepsilon_1}{r_1} = 0$ ,  $\frac{dV_0}{dt} \leq 0$ . We set  $\frac{dV_0}{dt} = 0$ , then  $S = \frac{A}{d}$ ,  $S' = 0$ . By first equation of (2.1), we obtain  $N = 0$ . Thus, the equilibrium  $E_{01}$  is globally asymptotically stable in the set  $\Omega = \{(S, N) | S \geq 0, N \geq 0\}$ .  $\square$

## 2.2. The S – T model

The S – N model is given by the following form.

$$\begin{cases} S'(t) = A - dS(t) - u_2 S(t) T(t), \\ T'(t) = r_2 u_2 S(t) T(t) - (d + \varepsilon_2) T(t). \end{cases} \quad (2.4)$$

By a similar argument to S – N model, S – T model possesses the similar dynamical behavior. There is an absorbing number

$$Q_2 = \frac{Ar_2 u_2}{d(d + \varepsilon_2)},$$

which depicts the dynamic behavior of this model.

**Theorem 2.4.** The following statements hold.

- (i) Assume  $Q_2 \leq 1$ . Then system (2.4) has a unique equilibrium  $E_{11} = (\frac{A}{d}, 0)$ , which is globally asymptotically stable in the set  $\Omega_1 = \{(S, N) | S \geq 0, T \geq 0\}$ ;
- (ii) Assume  $Q_2 > 1$ , then system (2.4) has two equilibria  $E_{11}$  and  $E_{12} = (\frac{d+\varepsilon_2}{r_2 u_2}, \frac{Ar_2 u_2 - d(d+\varepsilon_2)}{u_2(d+\varepsilon_2)})$ . In this case,  $E_{11}$  is unstable, and  $E_{12}$  is globally asymptotically stable in the set  $\Omega'_1 = \{(S, N) | S \geq 0, T > 0\}$ .

**Remark 2.1.** By the above results, the absorbing number  $Q_1 > 1$  (or  $Q_2 > 1$ ) is necessary condition for the permanence of normal cells (or tumor cells).

## 3. The model with competition

### 3.1. The S – N – T model

In Section 2, we analysis the S – N and S – T model, respectively. In this section, we consider the relationship between  $N$ ,  $T$  and  $S$ . The model is formulated as the form below.

$$\begin{cases} S'(t) = A - dS(t) - u_1 S(t) N(t) - u_2 S(t) T(t), \\ N'(t) = r_1 u_1 S(t) N(t) - (d + \varepsilon_1) N(t), \\ T'(t) = r_2 u_2 S(t) T(t) - (d + \varepsilon_2) T(t). \end{cases} \quad (3.1)$$

In the sequel, we always assume that absorbing numbers  $Q_1, Q_2 > 1$ . Because  $Q_1 \leq 1$  (or  $Q_2 \leq 1$ ) leads to the extinction of normal cells (or tumor cells). Firstly, we discuss the stability of equilibrium

$$E_{21} = (S_{21}, N_{21}, T_{21}) = \left( \frac{d + \varepsilon_1}{r_1 u_1}, \frac{Ar_1 u_1 - d(d + \varepsilon_1)}{u_1(d + \varepsilon_1)}, 0 \right)$$

and

$$E_{22} = (S_{22}, N_{22}, T_{22}) = \left( \frac{d + \varepsilon_2}{r_2 u_2}, 0, \frac{Ar_2 u_2 - d(d + \varepsilon_2)}{u_2(d + \varepsilon_2)} \right).$$

In order to examine local stability of each equilibrium, we should compute the eigenvalues of the linearized operator for system (3.1) at each equilibrium. Consider the equilibrium  $E_{21}$ , the Jacobian matrix of (3.1) is obtained as follows

$$J = \begin{bmatrix} -d - \frac{Ar_1 u_1 - d(d + \varepsilon_1)}{d + \varepsilon_1} & -\frac{d + \varepsilon_1}{r_1} & -\frac{u_2(d + \varepsilon_1)}{r_1 u_1} \\ r_1 \left[ \frac{Ar_1 u_1 - d(d + \varepsilon_1)}{d + \varepsilon_1} \right] & 0 & 0 \\ 0 & 0 & \frac{r_2 u_2(d + \varepsilon_1)}{r_1 u_1} - (d + \varepsilon_2) \end{bmatrix}.$$

The corresponding characteristic equation is

$$(\lambda^2 + p_1 \lambda + p_2)(\lambda - p_3) = 0.$$

where  $p_1 = \frac{Ar_1 u_1}{d + \varepsilon_1} > 0$ ,  $p_2 = Ar_1 u_1 - d(d + \varepsilon_1) > 0$ ,  $p_3 = (\frac{Q_2}{Q_1} - 1)(d + \varepsilon_2)$ . By Eq. (2.3), it is easy to know that the stability of equilibrium  $E_{21}$  depends on the sign of  $\frac{Q_2}{Q_1} - 1$ . Thus the follow theorem is obvious.

**Theorem 3.1.** If  $Q_1 > Q_2$ , then the equilibrium  $E_{21}$  is locally asymptotically stable; If  $Q_1 < Q_2$ , then the equilibrium  $E_{21}$  is unstable.

The next theorem, we show that the equilibrium  $E_{21}$  is globally asymptotically stable when  $Q_1 > Q_2$ .

**Theorem 3.2.** Assume that  $Q_1 > Q_2$ , then the equilibrium  $E_{21}$  is globally asymptotically stable in the set  $\Lambda = \{(S, N, T) | S \geq 0, N \geq 0, T \geq 0\}$ .

**Proof.** We define a Lyapunov function by

$$V_1(S, N, T) = S - S_{21} - S_{21} \ln \frac{S}{S_{21}} + \frac{1}{r_1} \left( N - N_{21} - N_{21} \ln \frac{N}{N_{21}} \right) + \frac{T}{r_2}. \quad (3.2)$$

Differentiating (3.2) with respect  $t$  along solutions of (3.1) in  $\Lambda$ , we obtain

$$\begin{aligned} \frac{dV_1}{dt} &= \frac{dS}{dt} - \frac{S_{21}}{S} \frac{dS}{dt} + \frac{1}{r_1} \left( \frac{dN}{dt} - \frac{N_{21}}{N} \frac{dN}{dt} \right) + \frac{1}{r_2} \frac{dT}{dt} \\ &= A - dS - u_1 SN - u_2 ST + u_1 SN - \frac{d + \varepsilon_1}{r_1} N + u_2 ST \\ &\quad - \frac{d + \varepsilon_2}{r_2} T - \frac{S_{21}}{S} (A - dS - u_1 SN - u_2 ST) \\ &\quad - N_{21} \left( u_1 S - \frac{d + \varepsilon_1}{r_1} \right) \\ &= (A - dS) \left( 1 - \frac{S_{21}}{S} \right) - \frac{(d + \varepsilon_1)N}{r_1} - \frac{(d + \varepsilon_2)T}{r_2} + S_{21} u_1 N \\ &\quad + S_{21} u_2 T - N_{21} \left( u_1 S - \frac{d + \varepsilon_1}{r_1} \right) \\ &= (A - dS) \left( 1 - \frac{S_{21}}{S} \right) - N_{21} \left( u_1 S - \frac{d + \varepsilon_1}{r_1} \right) \\ &\quad + \left( S_{21} u_1 - \frac{d + \varepsilon_1}{r_1} \right) N + \left( S_{21} u_2 - \frac{d + \varepsilon_2}{r_2} \right) T \end{aligned}$$

For the sake of simplicity, we set

$$x = (A - dS) \left( 1 - \frac{S_{21}}{S} \right) - N_{21} \left( u_1 S - \frac{d + \varepsilon_1}{r_1} \right), \quad (3.3)$$

$$y = \left( S_{21} u_1 - \frac{d + \varepsilon_1}{r_1} \right) N, \quad (3.4)$$

$$z = \left( S_{21}u_2 - \frac{d + \varepsilon_2}{r_2} \right) T. \quad (3.5)$$

Substituting  $S_{21} = \frac{d + \varepsilon_1}{r_1 u_1}$  and  $N_{21} = \frac{Ar_1 u_1 - d(d + \varepsilon_1)}{u_1(d + \varepsilon_1)}$  into (3.3)–(3.5), it follows that

$$x = -\frac{A}{SS_{21}}(S - S_{21})^2 \leq 0,$$

$$y = 0,$$

$$z = \frac{d(d + \varepsilon_1)(d + \varepsilon_2)(Q_2 - Q_1)}{Ar_1 r_2 u_1} T \leq 0.$$

Using similar arguments to these in Wang et al. [32], we consider the set

$$\Lambda_1 = \left\{ (S(t), N(t), T(t)) \mid \frac{dV_1}{dt} = 0 \right\}.$$

Let  $\frac{dV_1}{dt} = 0$ . Then we have from (3.3)–(3.5) that  $x = z = 0$ . And this implies  $S = S_{21}$ ,  $T = 0$ . It shows by first equation of (3.1) that

$$\frac{dS(t)}{dt} = A - dS_{21} - u_1 S_{21} N(t) = 0. \quad (3.6)$$

Hence,  $N = N_{21}$ . Thus, the largest invariant set of (3.1) contained in  $\Lambda_1$  is  $E_{21}$ . By the Lyapunov–Lasalle theorem, all solutions of system (3.1) in  $\Lambda$  approach  $E_{21}$  as  $t \rightarrow +\infty$ .  $\square$

**Remark 3.1.** Analogue to the equilibrium  $E_{21}$ , the stability of equilibrium  $E_{22}$  also depends on the sign of  $\frac{Q_2}{Q_1} - 1$ . Thus the following theorem is obvious.

**Theorem 3.3.** If  $Q_1 < Q_2$ , then the equilibrium  $E_{22}$  is globally asymptotically stable in the set  $\Lambda = \{(S, N, T) \mid S \geq 0, N \geq 0, T \geq 0\}$ ; If  $Q_1 > Q_2$ , then the equilibrium  $E_{22}$  is unstable.

Otherwise, in the case of  $Q_1 = Q_2$ , it implies that  $\frac{Ar_1 u_1}{d(d + \varepsilon_2)} = \frac{Ar_2 \varepsilon_2}{d(d + \varepsilon_2)}$ . Thus, we have  $\frac{r_1 u_1}{d + \varepsilon_1} = \frac{r_2 \varepsilon_2}{d + \varepsilon_2}$ , we calculate the equilibrium in system (3.1). Hence,

$$\begin{cases} A - dS(t) - u_1 S(t)N(t) - u_2 S(t)T(t) = 0, \\ r_1 u_1 S(t)N(t) - (d + \varepsilon_1)N(t) = 0, \\ r_2 u_2 S(t)T(t) - (d + \varepsilon_2)T(t) = 0. \end{cases} \quad (3.7)$$

By the second and third equation, we have  $S_* = \frac{d + \varepsilon_1}{r_1 u_1} = \frac{d + \varepsilon_2}{r_2 u_2}$ . Plugging  $S_* = \frac{d + \varepsilon_1}{r_1 u_1} = \frac{d + \varepsilon_2}{r_2 u_2}$  into the first equation in system (3.7), we find

$$u_1 N + u_2 T = d(Q_1 - 1). \quad (3.8)$$

Hence, all the points on the segment (3.8) are equilibrium points with  $S_* = \frac{d + \varepsilon_1}{r_1 u_1} = \frac{d + \varepsilon_2}{r_2 u_2}$ . By linearization of (3.1) at a constant solution  $(S_*, N_*, T_*)$ , we get the Jacobian matrix

$$L = \begin{bmatrix} -d - u_1 N_* - u_2 T_* & -u_1 S_* & -u_2 S_* \\ r_1 u_1 N_* & r_1 u_1 S_* - (d + \varepsilon_1) & 0 \\ r_2 u_2 T_* & 0 & r_2 u_2 S_* - (d + \varepsilon_2) \end{bmatrix}. \quad (3.9)$$

We set  $u_1 N_* + u_2 T_* = d(Q_1 - 1)$ ,  $S_* = \frac{d + \varepsilon_1}{r_1 u_1} = \frac{d + \varepsilon_2}{r_2 u_2}$ , then get the corresponding characteristic equation:

$$\lambda(\lambda^2 + dQ_1 \lambda + u_1(d + \varepsilon_1)N_* + u_2(d + \varepsilon_2)T_*) = 0.$$

Hence, the eigenvalues of  $L$  are simply given by  $\lambda_1 = 0$ ,  $\lambda_2 + \lambda_3 = -dQ_1 < 0$ ,  $\lambda_2 \lambda_3 = u_1(d + \varepsilon_1)N_* + u_2(d + \varepsilon_2)T_* > 0$ . Thus,  $\lambda_1 = 0$ ,  $\text{Re} \lambda_2 < 0$ ,  $\text{Re} \lambda_3 < 0$ , which implies every equilibrium in the segment  $u_1 N + u_2 T = d(Q_1 - 1)$ ,  $N \geq 0$ ,  $T \geq 0$  is an attractor in a certain direction by Zhang [33], see Fig. 5.

**Theorem 3.4.** If  $Q_1 = Q_2$ , the solutions of system (3.1) will tend to the segment  $u_1 N + u_2 T = d(Q_1 - 1)$ .

**Remark 3.2.** From the above analysis, it is easy to see that the final survival is the one whose absorbing number is bigger in competition between normal cells and tumor cells. There are six characteristics of cancer have been proposed: self-sufficiency in growth signalling, insensitivity to anti-growth signals, evasion of apoptosis, enabling of a limitless replicative potential, induction and sustainment of angiogenesis, activation of metastasis and invasion of tissue, see [7], which lead to  $Q_2 > Q_1$  in general. Thus, in the body of cancer patients (in vivo), it always hold that  $Q_2 > Q_1$ . It results in the extinction of normal cells, and the patient will die.

### 3.2. The effect of M1 virus

In order to see the potent oncolytic efficacy and high tumor tropism of M1, we always assume that  $Q_2 > Q_1 > 1$ . In this case, it is proved that without the aid of M1 virus, normal cells will extinct and patient will die by previous section. However, when the M1 virus is considered, the result will be different.

We are eager to find the condition which ensure the extinction of tumor cells. Thus, we set  $T = 0$  in system (1.1). By simple calculating, it is obvious that there is an equilibrium

$$E_{31} = (S_{31}, N_{31}, T_{31}, M_{31}) = \left( \frac{d + \varepsilon_1}{r_1 u_1}, \frac{Ar_1 u_1 - d(d + \varepsilon_1)}{u_1(d + \varepsilon_1)}, 0, \frac{B}{d + \varepsilon_3} \right).$$

And  $E_{31}$  is also the equilibrium for system (3.1) in the case of  $Q_1 = Q_2$ . Linearizing operator for system (1.1) at equilibrium  $E_{31}$ , the Jacobian matrix of (1.1) is

$$A = \begin{bmatrix} -d - \frac{Ar_1 u_1 - d(d + \varepsilon_1)}{d + \varepsilon_1} & -\frac{d + \varepsilon_1}{r_1} & -\frac{u_2(d + \varepsilon_1)}{r_1 u_1} & 0 \\ r_1 \left[ \frac{Ar_1 u_1 - d(d + \varepsilon_1)}{d + \varepsilon_1} \right] & 0 & 0 & 0 \\ 0 & 0 & \frac{r_2 u_2(d + \varepsilon_1)}{r_1 u_1} - (d + \varepsilon_2) - \frac{u_3 B}{d + \varepsilon_3} & 0 \\ 0 & 0 & \frac{r_3 u_3 B}{d + \varepsilon_3} & -(d + \varepsilon_3) \end{bmatrix}.$$

By Theorem 3.1, we see that  $\lambda = \frac{r_2 u_2(d + \varepsilon_1)}{r_1 u_1} - (d + \varepsilon_2) - \frac{u_3 B}{d + \varepsilon_3}$  dominates the stability of equilibrium  $E_{31}$ .

**Theorem 3.5.** Assume that  $Q_2 \geq Q_1 > 1$ . Then  $E_{31}$  is locally asymptotically stable if  $Q_2 < Q_1 + \frac{r_1 u_1 u_3 AB}{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)}$ , and is unstable if  $Q_2 > Q_1 + \frac{r_1 u_1 u_3 AB}{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)}$ .

**Proof.** If  $\frac{r_2 u_2(d + \varepsilon_1)}{r_1 u_1} - (d + \varepsilon_2) - \frac{u_3 B}{d + \varepsilon_3} < 0$ , then

$$\begin{aligned} r_2 u_2(d + \varepsilon_1) - r_1 u_1(d + \varepsilon_2) - \frac{r_1 u_1 u_3 B}{d + \varepsilon_3} &< 0 \\ \Rightarrow \frac{r_2 u_2}{d + \varepsilon_2} - \frac{r_1 u_1}{d + \varepsilon_1} - \frac{r_1 u_1 u_3 B}{(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)} &< 0 \\ \Rightarrow Q_2 - Q_1 - \frac{r_1 u_1 u_3 AB}{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)} &< 0. \end{aligned}$$

The result follows now directly from Theorem 3.1.  $\square$

**Theorem 3.6.** Assume that  $Q_2 \geq Q_1 > 1$ , then the equilibrium  $E_{31}$  is globally asymptotically stable in the set  $\Lambda_2 = \{(S, N, T, M) \mid S \geq 0, N \geq 0, T \geq 0, M \geq 0\}$  if  $Q_2 < Q_1 + \frac{r_1 u_1 u_3 AB}{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)}$ .

**Proof.** We define a Lyapunov function by

$$\begin{aligned} V_2(S, N, T, M) = S - S_{31} - S_{31} \ln \frac{S}{S_{31}} + \frac{1}{r_1} \left( N - N_{31} - N_{31} \ln \frac{N}{N_{31}} \right) \\ + \frac{T}{r_2} + \frac{1}{r_2 r_3} \left( M - M_{31} - M_{31} \ln \frac{M}{M_{31}} \right). \end{aligned} \quad (3.10)$$



Differentiating (3.10) with respect  $t$  along solutions of (1.1) in  $\Lambda_2$ , we obtain

$$\begin{aligned} \frac{dV_2}{dt} &= \frac{dS}{dt} - \frac{S_{31}}{S} \frac{dS}{dt} + \frac{1}{r_1} \left( \frac{dN}{dt} - \frac{N_{31}}{N} \frac{dN}{dt} \right) + \frac{1}{r_2} \frac{dT}{dt} \\ &\quad + \frac{1}{r_2 r_3} \left( \frac{dM}{dt} - \frac{M_{31}}{M} \frac{dM}{dt} \right) \\ &= A - dS - u_1 SN - u_2 ST + u_1 SN - \frac{d + \varepsilon_1}{r_1} N + u_2 ST - \frac{d + \varepsilon_2}{r_2} T \\ &\quad - \frac{u_3}{r_2} TM + \frac{1}{r_2 r_3} [B + r_3 u_3 TM - (d + \varepsilon_3)M] \\ &\quad - \frac{S_{31}}{S} (A - dS - u_1 SN - u_2 ST) - N_{31} \left( u_1 S - \frac{d + \varepsilon_1}{r_1} \right) \\ &\quad - \frac{M_{31}}{r_2 r_3 M} [B + r_3 u_3 TM - (d + \varepsilon_3)M] \\ &= (A - dS) \left( 1 - \frac{S_{31}}{S} \right) - \frac{(d + \varepsilon_1)N}{r_1} - \frac{(d + \varepsilon_2)T}{r_2} + \frac{B}{r_2 r_3} \\ &\quad - \frac{d + \varepsilon_3}{r_2 r_3} M + S_{31} u_1 N + S_{31} u_2 T - N_{31} \left( u_1 S - \frac{d + \varepsilon_1}{r_1} \right) \\ &\quad - \frac{M_{31}}{r_2 r_3 M} [B + r_3 u_3 TM - (d + \varepsilon_3)M] \\ &= (A - dS) \left( 1 - \frac{S_{31}}{S} \right) - N_{31} \left( u_1 S - \frac{d + \varepsilon_1}{r_1} \right) \\ &\quad + \left( S_{31} u_1 - \frac{d + \varepsilon_1}{r_1} \right) N + \left( S_{31} u_2 - \frac{d + \varepsilon_2}{r_2} - \frac{M_{31} u_3}{r_2} \right) T \\ &\quad + \frac{1}{r_2 r_3} [B - (d + \varepsilon_3)M] \left( 1 - \frac{M_{31}}{M} \right). \end{aligned} \quad (3.11)$$

By (3.11), we set

$$w_1 = (A - dS) \left( 1 - \frac{S_{31}}{S} \right) - N_{31} \left( u_1 S - \frac{d + \varepsilon_1}{r_1} \right), \quad (3.12)$$

$$x_1 = \left( S_{31} u_1 - \frac{d + \varepsilon_1}{r_1} \right) N, \quad (3.13)$$

$$y_1 = \left( S_{31} u_2 - \frac{d + \varepsilon_2}{r_2} - \frac{M_{31} u_3}{r_2} \right) T, \quad (3.14)$$

$$z_1 = \frac{1}{r_2 r_3} [B - (d + \varepsilon_3)M] \left( 1 - \frac{M_{31}}{M} \right). \quad (3.15)$$

Substituting  $S_{31} = \frac{d + \varepsilon_1}{r_1 u_1}$ ,  $N_{31} = \frac{Ar_1 u_1 - d(d + \varepsilon_1)}{u_1(d + \varepsilon_1)}$  and  $M_{31} = \frac{B}{d + \varepsilon_3}$  into (3.12)–(3.15), we have

$$w_1 = -\frac{A}{SS_{31}} (S - S_{31})^2 \leq 0$$

$$x_1 = 0,$$

$$y_1 = \frac{d(d + \varepsilon_1)(d + \varepsilon_2)}{Ar_1 r_2 u_1} \left[ Q_2 - Q_1 - \frac{r_1 u_1 u_3 AB}{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)} \right] T < 0,$$

$$z_1 = -\frac{[(d + \varepsilon_3)M - B]^2}{r_2 r_3 (d + \varepsilon_3)M} \leq 0.$$

Set

$$\Lambda_3 = \left\{ (S(t), N(t), T(t), M(t)) \mid \frac{dV_2}{dt} = 0 \right\}$$

Let  $\frac{dV_2}{dt} = 0$ . Then  $S = S_{31}$ ,  $T = 0$ ,  $M = M_{31}$ . Hence, from (1.1), it is easy to see that  $N = N_{31}$ . Thus, the largest invariant set of (1.1) contained in  $\Lambda_3$  is  $E_{31}$ . By the Lyapunov–Lasalle theorem, all solutions of system (1.1) in  $\Lambda_2$  approach  $E_{31}$  as  $t \rightarrow +\infty$ .  $\square$

**Remark 3.3.** By this Theorem, it is easy to see the tumor cell  $T$  becomes extinct, when  $Q_2 < Q_1 + \frac{r_1 u_1 u_3 AB}{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)}$ . Hence,  $B > \frac{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)(Q_2 - Q_1)}{r_1 u_1 u_3 AB}$  is the effective dosage for cancer. In particular, if  $Q_1 = Q_2$ , then for every  $B > 0$ , tumor cell  $T$  will die out, and there is no positive equilibrium. Because the equilibrium  $E_{31}$  is globally stable in  $\Lambda_2$ . Thus, we claim that little drug dose will lead to the extinction of  $T$ , as  $Q_1 = Q_2$  (i.e. for every  $B > 0$ ,  $T(t)$  will tend to 0 as  $t \rightarrow \infty$ ).

We claim that the minimum effective dosage of medication equals to

$$B_0 = \frac{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)(Q_2 - Q_1)}{r_1 u_1 u_3 AB}.$$

By Theorem 3.6, it is easy to know that tumor cells will die out as  $t \rightarrow +\infty$  whenever  $B > B_0$ . Thus, it is sufficient to show that tumor cells do not extinct as  $t \rightarrow +\infty$  whenever  $B < B_0$ . Before turning to the main result, we need following preliminary result due to Thieme (Theorem 4.5) [28], also see [10].

**Lemma 3.1.** Let  $X$  be a locally compact metric space and it is the union of two disjoint subsets  $X_1$  and  $X_2$ , with  $X_2$  be compact in  $X$  and  $X_1$  be open and forward invariant under the continuous semiflow  $\Phi$  on  $X$ . Assume that  $\Omega_2$ ,

$$\Omega_2 = \bigcup_{y \in Y_2} \omega(y), \quad Y_2 = \{x \in X_2; \Phi_t(x) \in X_2, \forall t > 0\},$$

has an acyclic isolated covering  $M = \bigcup_{k=1}^m M_k$ . If each part  $M_k$  of  $M$  is a weak repeller for  $X_1$ , then  $X_2$  is a uniform strong repeller for  $X_1$ .

**Theorem 3.7.** If  $Q_2 > Q_1 > 1$ , and  $Q_2 > Q_1 + \frac{r_1 u_1 u_3 AB}{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)}$ , then population  $T$  is uniformly persistent, i.e. there exists a positive constant  $\sigma$ , such that positive solutions of system (1.1) satisfy  $\liminf_{t \rightarrow \infty} T(t) > \sigma$ .

**Proof.** By (1.3), it is easy to see that system (1.1) is point dissipative. We set

$$X = R_+^4 = \left\{ (S, N, T, M) \mid S \geq 0, N \geq 0, T \geq 0, M \geq 0, \right. \\ \left. S + \frac{1}{r_1} N + \frac{1}{r_2} T + \frac{1}{r_2 r_3} M \leq \frac{A_1}{d} + 1 \right\},$$

$$X_1 = \left\{ (S, N, T, M) \in W \mid T > 0, \right. \\ \left. S + \frac{1}{r_1} N + \frac{1}{r_2} T + \frac{1}{r_2 r_3} M \leq \frac{A_1}{d} + 1 \right\},$$

$$X_2 = X \setminus X_1 = \left\{ (S, N, 0, M) \mid S \geq 0, N \geq 0, M \geq 0, \right. \\ \left. S + \frac{1}{r_1} N + \frac{1}{r_2} T + \frac{1}{r_2 r_3} M \leq \frac{A_1}{d} + 1 \right\}.$$

To prove theorem it is sufficient to show that  $X_2$  is uniformly strong repeller for  $X_1$ . Using Lemma 3.1, it suffice to verify the conditions of Lemma 3.1. It is clear that  $X$  be locally compact,  $X_2$  is compact and  $X_1$  is forward invariant. And there are two equilibria  $E_{00} = (\frac{A}{d}, 0, 0, \frac{B}{d + \varepsilon_3})$ ,  $E_{31} = (S_{31}, N_{31}, 0, M_{31})$  in  $X_2$  for system (1.1). We consider the system (1.1) in  $X_2$ .

$$\begin{cases} S'(t) = A - dS(t) - u_1 S(t)N(t), \\ N'(t) = r_1 u_1 S(t)N(t) - (d + \varepsilon_1)N(t), \\ M'(t) = B - (d + \varepsilon_3)M(t). \end{cases} \quad (3.16)$$

As  $Q_1 > 1$ , we see that  $E_1 = (S_{31}, N_{31}, M_{31})$  is globally stable for solutions  $(S(t), N(t), M(t))$  to (3.16) with positive initial value by Theorem 2.4. Moreover, let  $Y = \{(S, 0, M) | S \geq 0, M \geq 0\}$ , then  $Y$  is positively invariant for (3.16) and the solutions to (3.16) in  $Y$  approach  $E_0 = (\frac{A}{d}, 0, \frac{B}{d+\varepsilon_3})$  as  $t \rightarrow \infty$  and become zero or unbounded as  $t \rightarrow -\infty$ . Thus,  $\Omega_2 = \{E_{00}, E_{31}\}$ ,  $M = M_1 \cup M_2 = E_{31} \cup E_{00}$ . Therefore, we know that  $M$  is acyclic in  $X_2$ .

By Theorem 3.1 and Jacobian matrix at  $E_{00}$ , it is easy to show that  $E_{00}$  and  $E_{31}$  are hyperbolic as

$$Q_2 > Q_1 > 1, Q_2 > Q_1 + \frac{r_1 u_1 u_3 AB}{d(d+\varepsilon_1)(d+\varepsilon_2)(d+\varepsilon_3)},$$

which implies that  $E_{00}$  and  $E_{31}$  are isolated in  $X_2$ . By the above discuss, we know that  $\Omega_2$  has an acyclic isolated covering  $M = E_{31} \cup E_{00}$ .

Next, we need to show that each part  $M_k (k=1, 2)$  of  $M$  is a weak repeller for  $X_1$ . It suffice to show that  $W^s(E_{31}) \cap X_1 = \emptyset$  and  $W^s(E_{00}) \cap X_1 = \emptyset$ , where  $W^s(E_{31})$  denotes the stable manifold of  $E_{31}$ , and  $W^s(E_{00})$  denotes the stable manifold of  $E_{00}$ . Suppose  $W^s(E_{31}) \cap X_1 \neq \emptyset$ . Then there is a solution of (1.1) such that

$$\lim_{t \rightarrow \infty} (S(t), N(t), T(t), M(t)) \rightarrow E_{31}.$$

Thus, it follows from the third equation of (1.1) that for any  $\varepsilon > 0$ , there exists positive number  $t_0$ , such that

$$T'(t) \geq T \left[ r_2 u_2 \left( \frac{d+\varepsilon_1}{r_1 u_1} - \varepsilon \right) - (d+\varepsilon_2) - \frac{u_3 B}{d+\varepsilon_3} \right], \forall t \geq t_0. \quad (3.17)$$

We denote

$$g(\varepsilon) = r_2 u_2 \left( \frac{d+\varepsilon_1}{r_1 u_1} - \varepsilon \right) - (d+\varepsilon_2) - \frac{u_3 B}{d+\varepsilon_3}.$$

Then for  $t \geq t_0$ ,  $T'(t) \geq g(\varepsilon)T$ . Since

$$Q_2 > Q_1 + \frac{r_1 u_1 u_3 AB}{d(d+\varepsilon_1)(d+\varepsilon_2)(d+\varepsilon_3)},$$

we can choose  $\varepsilon$  small enough such that  $g(\varepsilon) > 0$ . Then (3.17) implies that  $T(t) \rightarrow \infty$  as  $t \rightarrow \infty$ , which contradicts that positive solutions are ultimately bounded. Therefore,  $W^s(E_{31}) \cap X_1 = \emptyset$ . Similarly, we can prove that  $W^s(E_{00}) \cap X_1 = \emptyset$ . The proof is completed.  $\square$

**Remark 3.4.** By Theorems 3.2 and 3.6, we see that M1 virus is potent oncolytic efficacy and high tumor tropism which verify results in [19]. Besides, by Theorem 3.7, it is easy to see that the minimum effective dosage of medication can be explicitly calculated by our method, i.e.

$$B_0 = \frac{d(d+\varepsilon_1)(d+\varepsilon_2)(d+\varepsilon_3)(Q_2 - Q_1)}{r_1 u_1 u_3 A}. \quad (3.18)$$

Indeed, when  $B < B_0$ ,  $C \equiv \frac{Ar_1 u_1}{d(d+\varepsilon_1)} - [\frac{u_2(B_0-B)}{r_3 u_3 M_{32}^2} + d] > 0$ , then there exist a positive equilibrium  $E_{32} = (S_{32}, N_{32}, T_{32}, M_{32})$ , where  $S_{32} = \frac{d+\varepsilon_1}{r_1 u_1}$ ,  $M_{32} = \frac{d(d+\varepsilon_1)(d+\varepsilon_2)(Q_2-Q_1)}{Ar_1 u_1 u_3}$ ,  $T_{32} = \frac{B_0-B}{r_3 u_3 M_{32}^2}$ ,  $N_{32} = \frac{C}{u_1}$ .

#### 4. Simulations and biological interpretations

In this section, we carry out numerical simulations to illustrate the theoretical results obtained in Sections 2 and 3, and some biological interpretations are given.

Simulation of  $S-N$  model (2.1) is done with the following parameter values and initial conditions:  $A = 0.02$ ,  $d = 0.02$ ,  $u_1 = 0.2$ ,  $r_1 = 0.8$ ,  $\varepsilon_1 = 0.01$ ,  $S_0 = 0.1$ ,  $N_0 = 0.2$ , see Fig. 1. By the absorbing formula (2.2),  $Q_1 = 5.3333 > 1$  which implies that normal cells can persist at the population level  $N = 0.4312$ . Otherwise, normal




Fig. 1.  $S-N$  model with  $Q_1 > 1$ .








Fig. 2.  $S-N$  model with  $Q_1 < 1$ .

cells can die out in  $S-N$  model (2.1), with the parameter values:  $A = 0.02$ ,  $d = 0.02$ ,  $u_1 = 0.03$ ,  $r_1 = 0.8$ ,  $\varepsilon_1 = 0.01$ ,  $S_0 = 0.5$ ,  $N_0 = 0.8$ , thus  $Q_1 = 0.8 < 1$ , see Fig. 2. Besides, it has the similar behavior as we adjust the  $\varepsilon_1 = 0.14$  which implies  $Q_1 = 1$ , see Fig. 3. Hence, we regard the absorbing as a index of net reproductive rate: as  $Q_1 > 1$ , the cells can persist at the population level, otherwise, as  $Q_1 \leq 1$ , the cells will die out. Indeed, system (2.1) itself reflect this property. We transform the equation about the component  $N$  in (2.1) to

$$\frac{N'(t)}{N(t)} = r_1 u_1 S(t) - (d + \varepsilon_1).$$

The term  $-(d + \varepsilon_1)$  reflects the average removal rate per unit of time, thus the  $\frac{1}{(d+\varepsilon_1)}$  is the average lifetime in compartment  $N$ . Combining with the term  $r_1 u_1 S(t)$ , we get that the recruitment due to each individual in component  $N$  in its lifetime is  $\frac{r_1 u_1 S_*}{d+\varepsilon_1}$ , where  $S_*$  is the output by every individual in its lifetime. The similar argument on the first equation in (2.1) shows that every individual in compartment  $S$  produces  $S_* = \frac{A}{d}$ . Hence, every individual in component  $N$  produces  $Q_1 = \frac{r_1 u_1 A}{d(d+\varepsilon_1)}$  in its lifetime. The discussion on  $S-T$  model is similar. Thus, We always assume  $Q_1, Q_2 > 1$  for later discussion.

In  $S-N-T$  model, competitive behavior between normal cells and tumor cells depends on the absorbing number  $Q_1, Q_2$ . In Fig. 4, we choose the same  $A, d, u_1, r_1, \varepsilon_1$  as in Fig. 1, and

Fig. 3.  $S-N$  Model,  $Q_1 = 1$ .Fig. 5.  $S-N-T$  Model,  $Q_1 = Q_2$ .Fig. 4.  $S-N-T$  Model,  $Q_1 < Q_2$ .Fig. 6.  $S-N-T-M$  Model,  $Q_1 = Q_2$ .

assume  $r_2 = 0.8$ ,  $u_2 = 0.5$ ,  $\varepsilon_2 = 0.008$ . By simple calculating, we get  $Q_1 = 5.3333$ ,  $Q_2 = 14.2857$ , thus  $Q_1 < Q_2$ . Using Theorem 3.3, we see that the normal cells will extinct and tumor cells will persist, which consists with our numerical modeling in Fig. 4. As the status of  $N$  and  $T$  are symmetric in system (3.1), thus if  $Q_1 > Q_2$ , the component  $N$  can survive, and component  $T$  will extinct.

On other hand, if we assume  $A = 0.02$ ,  $d = 0.02$ ,  $u_1 = 0.2$ ,  $r_1 = 0.8$ ,  $\varepsilon_1 = 0.01$ ,  $r_2 = 0.8$ ,  $u_2 = 0.4$ ,  $\varepsilon_2 = 0.04$ , then  $Q_1 = Q_2 = 5.3333$ , see Fig. 5. In Fig. 5, the red straight line is  $u_1N + u_2T = d(Q_1 - 1)$ , the blue lines denote the solution of (3.1) for initial value for  $(0.1, 0.04k, 0.02)$  and  $(0.1, 0.04k, 0.3)$ ,  $k = 1, 2, \dots, 15$ . We can see that all solutions tend to the points on the red straight line  $u_1N + u_2T = d(Q_1 - 1)$  that agrees with our result in Theorem 3.4. In addition, as we consider the M1 virus in system (3.1), the model will turn into system (1.1). Setting  $u_3 = 0.1$ ,  $r_3 = 0.5$ ,  $\varepsilon_3 = 0.01$ ,  $B = 0.01$ , the Fig. 5 changes into Fig. 6. Indeed,  $B$  can be chosen small enough, it will have similar behavior in Fig. 6, and the difference is just that the time should be longer for  $T$  approaching to 0. It also consists with our theoretical result in Theorem 3.6, Remark 3.3. When  $\varepsilon_1 = \varepsilon_2$ , we set  $H = u_1N + u_2T$ , then the system (3.1) will change to

$$\begin{cases} S'(t) = A - dS(t) - H(t), \\ H'(t) = (d + \varepsilon_1) \left( \frac{r_1 u_1}{d + \varepsilon_1} S(t) - 1 \right) H(t), \end{cases}$$

By the same argument on system (2.1), we see that the equilibrium  $(\frac{d+\varepsilon_1}{r_1 u_1}, d(Q_1 - 1))$  is globally stable in  $\mathbb{R}_+^2$  as  $Q_1 > 1$ . From the perspective of growth, we can also regard the component  $T$  as normal cells. Because tumor is just a synonym for a large number of diseases characterized by uncontrolled cell growth, so the absorbing number also can be regard as an index to distinguish the normal cell and tumor cell. In particular,  $Q_2$  is always bigger than the  $Q_1$ , due to the characteristic of tumor [7].

In Figs. 7 and 8, we choose the same  $A, d, u_1, r_1, \varepsilon_1, r_2, u_2, \varepsilon_2$  as in Fig. 1, and assume  $u_3 = 0.1, r_3 = 0.5, \varepsilon_3 = 0.01$ . Thus,  $Q_1 = 5.3333$ ,  $Q_2 = 14.2857$ . By (3.18), we get the minimum effective dosage  $B_0 = 0.0141$ . If we set  $B = B_0 - 0.01$ , the dynamic behavior is shown as Fig. 7. Otherwise, we set  $B = B_0 + 0.01$ , then the Fig. 4 changes to Fig. 8, which implies that the tumor cells become extinct, and normal cells persist at the normal population level  $N = 0.4312$  that is same as in Fig. 1. Thus, it illustrates the potent oncolytic efficacy of M1 virus as reported in [19]. These results consist with Theorems 3.6 and 3.7.

## 5. Conclusions and discussions

Indeed, we try to identify the absorbing number as an index to distinguish the normal cell and tumor cell. Besides, when the tumors absorbing number  $Q_2$  is smaller than the normal cells absorbing number  $Q_1$ , it implies it can not threaten patient's health. When  $Q_2 = Q_1$ , we can regard the component  $T$  as normal cells.




Fig. 7.  $S - N - T - M$  Model,  $Q_1 < Q_2$ ,  $B < B_0$ .




Fig. 8.  $S - N - T - M$  Model,  $Q_1 < Q_2$ ,  $B > B_0$ .

Because of the action of initial mutation in a cancer cell and the activation of the normal cells in the proto-oncogene, their cancer had cancer cells. So tumor is just a synonym for a large number of diseases characterized by uncontrolled cell growth. Thus, in particular,  $Q_2$  is always bigger than the  $Q_1$  due to the characteristic of tumor [7]. Only in this case, the growth of tumor cell will lead to the extinction of normal cell that threatens to patient's health as proved in Theorem 3.3. So the situation  $Q_1 = Q_2$  is not important in  $S - N - T - M$  model, though we have treat this situation in Section 3.2. In the situation  $Q_1 < Q_2$ , we focus our attention to the stability of equilibrium  $E_{31}$  because in this case, the therapy for cancer patients is efficient.

On the other hand, in Remark 3.4 we find the strictly positive equilibrium under certain conditions although we are not very interested in it, as the stability of this equilibrium implies that the onolytic treatment has little effect to the disease. We also proved that there exists a positive constant  $\sigma > 0$ , such that  $\liminf_{t \rightarrow \infty} T(t) > \sigma$  when the dose  $B$  is smaller than our minimum effective dosage of medication.

Our work is motivated by the experimental findings in Lin et al. [19] that M1 virus could be a candidate for systematic onolytic therapy. Thus, we formulated a prey-predator model with competition to illustrate the evolution of normal cell concentration due to the effect of M1 virus.

In the above analysis, we obtained two threshold values (the absorbing number)  $Q_1$  and  $Q_2$  which dominate the global evolution of system (1.1). Fortunately, our theoretic results on the model give an explanation of the experimental findings in Lin et al. [19]. For example, Theorem 2.3 describe the evolution of normal cell without tumor or M1 virus which reflect the growth of normal cells in healthy individual; Theorem 3.3 show the growth of cells in the body of cancer patient without treatment; The behavior of cells in the body of cancer patient with treatment is studied in Theorem 3.6. Combining Theorems 3.6 and 3.7, the explicit minimum effective dosage of medication

$$B = \frac{d(d + \varepsilon_1)(d + \varepsilon_2)(d + \varepsilon_3)(Q_2 - Q_1)}{r_1 u_1 u_3 A}$$

is obtained which is not reported in [19].

## References

- [1] A. Albert, M. Freedman, A.S. Perelson, Tumors and the immune system: the effects of a tumor growth modulator, *Math. Biosci.* 50 (1–2) (1980) 25–58.
- [2] S. Balachandran, M. Porosnicu, G.N. Barber, Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, ras, or myc function and involves the induction of apoptosis, *J. Virol.* 75 (7) (2001) 3474–3479.
- [3] C. DeLisi, A. Renshaw, Immune surveillance and neoplasia-1. a minimal mathematical model, *Bull. Math. Biol.* 39 (2) (1977) 201–221.
- [4] R.J. de Boer, P. Hogeweg, Interactions between macrophages and t-lymphocytes: tumor sneaking through intrinsic to helper t cell dynamics, *J. Theor. Biol.* 120 (1986) 331–351.
- [5] I.M. Dozmorov, V.A. Kuznetsov, The role of cellular ratios in the maintenance of organism immune homeostasis, in: R.V. Petrov, V.P. Lozovoy (Eds.), *Problems and Perspectives of Modern Immunology: Methodological Analysis* (in Russian), 1988, pp. 43–66.
- [6] Z. Grossman, G. Berke, Tumor escape from immune elimination, *J. Theor. Biol.* 83 (1980) 267–296.
- [7] D. Hanahan, R.A. Weinberg, The hallmarks of cancer, *Cell* 100 (1) (2000) 57–70.
- [8] H.W. Hethcote, The mathematics of infectious diseases, *SIAM Rev.* 42 (4) (2000) 599–653.
- [9] J.R. Hiernaux, R. Lefever, C. Uytendhoe, T. Boon, Tumor dormancy as a result of simple competition between tumor cells and cytolytic effector cells, in: G.W. Hoffman, J.G. Levy, G.T. Nepom (Eds.), *Paradoxes in Immunology*, CRC Press, Florida, 1986, pp. 95–109.
- [10] W.M. Hirsch, H.L. Smith, X.-Q. Zhao, Chain transitivity, attractivity and strong repellors for semidynamical systems, *J. Dyn. Diff. Equ.* 13 (2001) 107–131.
- [11] S.B. Hsu, S. Hubbell, P. Waltman, A mathematical theory for single-nutrient competition in continuous cultures of micro-organisms, *SIAM J. Appl. Math.* 32 (2) (1977) 366–383.
- [12] S.B. Hsu, P. Waltman, A survey of mathematical models of competition with an inhibitor, *Math. Biosci.* 187 (1) (2004) 53–91.
- [13] A. Jemal, F. Bray, et al., Global cancer statistics, *CA Cancer J. Clin.* 61 (2) (2011) 69–90.
- [14] N.L. Komarova, D. Wodarz, ODE models for onolytic virus dynamics, *J. Theor. Biol.* 263 (4) (2010) 530–543.
- [15] V.A. Kuznetsov, The dynamics of cellular immunological antitumor reactions. i. synthesis of a multi-level model, *Math. Meth. Syst. Theory* 1 (1979) 57–71.
- [16] V.A. Kuznetsov, I.A. Makalkin, M.A. Taylor, A.S. Perelson, Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis, *Bull. Math. Biol.* 56 (2) (1994) 295–321.
- [17] A.T. Look, T.J. Schriber, J.F. Nawrocki, W.H. Murphy, Computer simulation of the cellular immune response to malignant lymphoid cells: logic of approach, model design and laboratory verification, *Immunol.* 43 (1981) 677–690.
- [18] R. Lefever, T. Erneux, On the growth of cellular tissues under constant and fluctuating environmental conditions, in: P. Adley, A.F. Lawrence (Eds.), *Nonlinear Electrodynamics in Biological Systems*, Plenum Press, New York and London, 1984, pp. 287–305.
- [19] Y. Lin, H. Zhang, J. Liang, et al., Identification and characterization of alphavirus M1 as a selective onolytic virus targeting ZAP-defective human cancers, *Proc. Nat. Acad. Sci.* 111 (42) (2014) E4504–E4512.
- [20] R.L. Martuza, A. Malick, J.M. Markert, K.L. Ruffner, D.M. Coen, Experimental therapy of human glioma by means of a genetically engineered virus mutant, *Science* 252 (5007) (1991) 854–856.
- [21] S.J. Merrill, S. Sathananthan, Approximate Michaelis-Menten kinetics displayed in a stochastic model of cell-mediated cytotoxicity, *Math. Biosci.* 80 (1986) 223–238.
- [22] R.R. Mohler, K.S. Lee, Dynamic analysis and control of cancer, in: *Proceedings of International Conference on IEEE Engineering in Medicine and Biology Seattle*, 1989, pp. 1–2.
- [23] A.S. Perelson, C.A. Macken, Kinetics of cell-mediated cytotoxicity: stochastic and deterministic multistage models, *Math. Biosci.* 170 (1984) 161–194.
- [24] P. van den Driessche, J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, *Math. Biosci.* 180 (2002) 29–48.



- [25] J.G. Sinkovics, J.C. Horvath, Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers, *Arch Immunol. Ther. Exp.* 56 (Suppl 1) (2008) 1–59.
- [26] D.F. Stojdl, et al., Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus, *Nat. Med.* 6 (7) (2000) 821–825.
- [27] Y. Tao, Q. Guo, The competitive dynamics between tumor cells, a replication-competent virus and an immune response, *J. Math. Biol.* 51 (1) (2005) 37–74.
- [28] H.R. Thieme, Persistence under relaxed point-dissipativity (with application to an endemic model), *SIAM J. Math. Anal.* 24 (1993) 407–435.
- [29] R.M. Thorn, C.S. Henney, Kinetic analysis of target cell destruction by effector  $t$  cell, *J. Immunol.* 117 (1976) 2213–2219.
- [30] R.M. Thorn, C.S. Henney, Kinetic analysis of target cell destruction by effector cells, II. changes in killer cell avidity as a function of time and dose, *J. Immunol.* 119 (1977) 1973–1978.
- [31] S. Wang, S. Wang, X. Song, Hopf bifurcation analysis in a delayed oncolytic virus dynamics with continuous control, *Nonlinear Dyn.* 67 (2012) 629–640.
- [32] W. Wang, X. Zou, Modeling the role of altruism of antibiotic-resistant bacteria, *J. Math. Biol.* 68 (6) (2014) 1317–1339.
- [33] Z. Zhang, T. Ding, W. Huang, Z. Dong, Qualitative theory of differential equations, in: *Translations of Mathematical Monographs*, vol. 101, American Mathematical Society, Providence, RI, USA, 1992.